News | SPECT Imaging | February 18, 2022

Already used in single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) for adult patients, Rapiscan is now approved for use in stress cardiac magnetic resonance imaging (CMR)

Already used in single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) for adult patients, Rapiscan is now approved for use in stress cardiac magnetic resonance imaging (CMR)

February 18, 2022 — GE Healthcare has announced that it has received approval from the European Medicines Agency (EMA) for additional imaging modalities for its stress agent Rapiscan (Regadenoson). Already an established pharmacological stress agent in SPECT MPI for adult patients, Rapiscan is now approved for use in Magnetic Resonance Imaging (MRI) as well as Computed Tomography (CT) and Positron Emission Tomography (PET).

Rapiscan simulates the effects of exercise in the hearts of adult patients unable to exercise and is used to aid the diagnosis of coronary artery disease (CAD). The approval for additional imaging modalities will enable Rapiscan to be used with an MR contrast agent in stress CMR to assess the function and blood flow of the heart, enabling radiologists/cardiologists to perform a single stress/rest/MRI protocol.

Stress CMR has shown high diagnostic performance (sensitivity and specificity of 90% and above) compared to gold standard invasive imaging for coronary artery disease and is recommended for use in the 2019 European Society of Cardiology guidelines for the diagnosis and management of chronic coronary syndromes, along with other non-invasive diagnostic tests, such as stress SPECT MPI.

Rapiscan can be used across a broad spectrum of patients as it does not require weight and age-based modifications or an infusion pump.

Dr Gianluca Pontone, Director of Cardiovascular Imaging Department, Monzino Cardiology Center at University of Milan said: “Our experience with Rapiscan in stress MR was very positive. We found it easy to use and very effective in helping to speed up the entire examination which was a key factor for us as was the high level of tolerance amongst patients.”

Dr Mark Hibberd, Chief Medical Officer at GE Healthcare Pharmaceutical Diagnostics, said: “Market authorization of the additional imaging modalities for Rapiscan could make it easier for more patients, who are unable to exercise, to have this stress test and aid radiologists and cardiologists in making assessments.”

GE Healthcare has the commercial rights to promote Rapiscan excluding US, Mexico and Canada.

GE Healthcare Pharmaceutical Diagnostics imaging agents support three patient procedures every second worldwide across MRI, X-ray/CT and nuclear medicine imaging. Its portfolio of cardiology products aims to support diagnosis and monitoring throughout the cardiac care pathway and aid treatment decisions across multiple pathologies with products available for use in interventional angiography laboratories, and in CT, MRI, Echocardiography and SPECT imaging.

For more information: www.gehealthcare.com

Related content:

FDA Adds Coronary CT Angiography Indication for GE Healthcare’s Visipaque Contrast Media

Deep Learning with SPECT Accurately Predicts Major Adverse Cardiac Events

Related Content

News | Radiology Business

June 29, 2022 — Siemens Healthineers and The Ohio State University Wexner Medical Center announced a new alliance, aimed ...

Time June 29, 2022
arrow
News | Coronavirus (COVID-19)

June 27, 2022 — Three articles and an accompanying editorial provide information on the effects of Long COVID in the ...

Time June 28, 2022
arrow
News | SNMMI

June 22, 2022 — Andrei Iagaru, MD, FACNM, professor of radiology (nuclear medicine) and chief of the Division of Nuclear ...

Time June 22, 2022
arrow
News | PET Imaging

June 21, 2022 — Markus Schwaiger, MD, a scientist known for his contributions to cardiac PET imaging, has been named as ...

Time June 21, 2022
arrow
News | SPECT Imaging

June 15, 2022 — A cardiac SPECT imaging system performs scans 10 to 100 times faster than current SPECT systems ...

Time June 15, 2022
arrow
News | PET Imaging

June 15, 2022 — Poor functional outcomes after a heart attack can be predicted with a new PET imaging agent, 68Ga-FAPI ...

Time June 15, 2022
arrow
News | PET Imaging

June 15, 2022 — Patients with severe obstructive sleep apnea (OSA) are less able to increase blood flow to the heart ...

Time June 15, 2022
arrow
News | Prostate Cancer

June 15, 2022 — Current guidelines used to plan salvage radiation treatments in patients with local recurrence of ...

Time June 15, 2022
arrow
News | PET-CT

June 14, 2022 — A novel artificial intelligence method can be used to generate high-quality “PET/CT” images and ...

Time June 14, 2022
arrow
News | SPECT-CT

June 13, 2022 — Siemens Healthineers has announced the Food and Drug Administration (FDA) clearance of the Symbia Pro ...

Time June 13, 2022
arrow
Subscribe Now